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Abstract
Rift Valley fever (RVF) is a viral zoonosis that primarily affects animals resulting in considerable economic losses due to death
and abortions among infected livestock. RVF also affects humans with clinical symptoms ranging from an influenza-like
illness to a hemorrhagic fever. Over the past years, RVF virus (RVFV) has caused severe outbreaks in livestock and humans
throughout Africa and regions of the world previously regarded as free of the virus. This situation prompts the need to
evaluate the diagnostic capacity and performance of laboratories worldwide. Diagnostic methods for RVFV detection
include virus isolation, antigen and antibody detection methods, and nucleic acid amplification techniques. Molecular
methods such as reverse-transcriptase polymerase chain reaction and other newly developed techniques allow for a rapid
and accurate detection of RVFV. This study aims to assess the efficiency and accurateness of RVFV molecular diagnostic
methods used by expert laboratories worldwide. Thirty expert laboratories from 16 countries received a panel of 14 samples
which included RVFV preparations representing several genetic lineages, a specificity control and negative controls. In this
study we present the results of the first international external quality assessment (EQA) for the molecular diagnosis of RVF.
Optimal results were reported by 64% of the analyses, 21% of the analyses achieved acceptable results and 15% of the
results revealed that there is need for improvement. Evenly good performances were achieved by specific protocols which
can therefore be recommended as an accurate molecular protocol for the diagnosis of RVF. Other protocols showed uneven
performances revealing the need for improved optimization and standardization of these protocols.
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Introduction
Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that
primarily affects animals but also has the capacity to infect
humans. An epizootic of RVF is usually first indicated by a wave of
unexplained abortions as infected pregnant livestock abort
virtually 100% of fetuses. The disease is less fatal to humans as
most human infections are asymptomatic and when clinical
symptoms appear they are in majority influenza-like. Nevertheless,
some cases may develop a severe RVF disease with variable
clinical signs. More severe cases occur in 2% of the RVF cases and
fall into three categories: liver necrosis with hemorrhaging, retinitis
with visual impairment and meningoencephalitis [1,2].
The causative agent of RVF, the RVF virus (RVFV), is a
negative-stranded RNA virus, a member of the genus Phlebovirus of
the Bunyaviridae family. The number of identified viral lineages of
RVFV has increased from 3 in an early analysis [3] to 7 in a 2007
study [4], and in the most recent report 15 distinct genetic groups
were reported [5]. Phylogenetic analysis shows that the virus
emerged in the mid-19th century, but it was first identified in 1930
during an outbreak of abortions and deaths among sheep in the
Rift Valley region of Kenya. In 1977–78, several millions of people
were infected and more than 600 died during a severe epidemic in
Egypt [6]. Since then, the geographical distribution of the virus
has widely spread and now includes most countries of the African
continent as well as Madagascar and the Arabian Peninsula.
During the past five years, outbreaks have been reported in Kenya
[7], Somalia, Tanzania [8], Sudan [9], Mayotte [10], Madagascar
[11], Swaziland, South Africa and Mauritania [12,13] Another
important concern is the increasing number of human fatalities
during the most recent outbreaks [14].
The emergence or re-emergence of RVFV activity is periodic and
associated with exceptionally heavy rainfalls which allow massive
breeding of flood-water Aedes mosquitoes with the capacity for
transovarial transmission [15] and other competent vectors such as
Anopheles and Culex species [9]. These mosquitoes may initiate
outbreaks among livestock, particularly breeds of cattle and sheep.
The virus can be transmitted to humans by mosquito bite or by
contact with infected tissues of domestic and wildlife ruminants. The
sudden onset of large numbers of abortions and fatalities in RVFV
affected livestock, resulting in the virus spread to humans can greatly
strain public health and veterinary infrastructures.
PLOS Neglected Tropical Diseases | www.plosntds.org 1 May 2013 | Volume 7 | Issue 5 | e2244
Unavailability of effective antiviral drugs and commercial
vaccines for human or animal use outside endemic countries,
including the US and Europe, and the recent spread of RVFV
beyond its usual boundaries has resulted in increased international
demand for qualified diagnostic tools for a rapid and accurate
diagnosis of RVF.
Diagnostic methods for RVFV detection include virus isolation
[16], antigen [17,18] and antibody detection methods [19–21] and
nucleic acid amplification techniques. Isolation procedures are
expensive, time-consuming and require high biocontainment
facilities. Serological methods such as antigen or antibody-
detection enzyme immunoassays (EIA) require several samples
and often lack sensitivity. Therefore, considerable efforts have
been made to develop molecular methods which allow a rapid,
accessible and accurate detection of RVFV. The use of direct
diagnostic methods such as molecular methods, can detect the
disease during the acute phase of the infection thus allowing
efficient patient management, avoiding nosocomial cases and
providing rapid outbreak response. Highly sensitive nucleic acid
detection methods have been developed including polymerase
chain reaction (PCR) assays such as reverse-transcriptase PCR
(RT-PCR) [22], real-time RT-PCR (qRT-PCR) [23–25] and
more recently real-time reverse-transcription loop-mediated iso-
thermal amplification (RT-LAMP) [26] and recombinase poly-
merase amplification assays (RPA) [27].
The performance of the different techniques applied for
molecular diagnosis of RVFV may vary between laboratories.
External quality assessment (EQA) studies to assess the quality of
RVFV molecular diagnostics have not been performed until now.
The EQA study allows the participating laboratories to monitor
the quality of current diagnosis, identify possible weaknesses of
particular diagnostic methods and evaluate their capacity for
surveillance activities. Therefore the first EQA study for the
molecular diagnosis of RVFV was organized by the European
Network for Diagnostics of ‘Imported’ Viral Diseases (ENIVD)
(http://www.enivd.org) in 2012. Using the results of this study, the
ENIVD can also provide support and advice to all laboratories
performing RVFV molecular diagnosis.
Materials and Methods
Call for participation
A total of 33 laboratories involved in diagnostics of RVF
infections were invited to participate in this study. Invitees were
selected from the register of ENIVD members, national/regional
reference laboratories for RVF or vector-borne diseases as well as
on the basis of their contributions to the literature relevant to this
topic. The participation to the study was open and free of charge
and included publication of the results in a comparative and
anonymous manner. This EQA was coordinated by the ENIVD
following comparable procedures used during previous studies
performed by the network [28,29].
Specimen preparation
A proficiency test panel of 14 samples was prepared which
included inactivated and stable RVFV preparations generated
from Vero E6 cell culture supernatants of different RVFV genetic
lineages and origin. Viral cell supernatants were inactivated by
heating for 1 h at 60uC and gamma irradiation (25 kilogray) to
assure their non-infectivity. A serum sample spiked with Toscana
virus, another phlebovirus, was included as a specificity control as
well as two negative controls. The RVFV positive samples selected
for this EQA panel are detailed in Table 1. Two dilutions of
sample Tambul/Egypt/1994 and 5 dilutions of sample F057/
Kenya/2007 were obtained by serial 10-fold dilutions and
included in the panel for sensitivity testing.
All virus material used for the preparation of the EQA panel
was obtained from cell culture and not from clinical samples of
infected patients. Therefore, there is no requirement for any
ethical statement in this study.
All samples were diluted with fresh thawed human plasma
previously confirmed as negative for RVFV. Aliquots of 100 ml
were number-coded, freeze dried for 24 h (Christ, AlphaI-5,
Hanau, Germany) and stored at 4uC until dispatched.
Validation and dispatch of the panel sets
Before dispatching the panels, 3 different sets of EQA samples
were tested and validated by 2 expert laboratories. For validation,
the samples were resuspended in 100 ml of water and the RNA
extracted using the QIAamp viral RNA minikit (Qiagen, Hilden,
Germany). The number of RVFV genome copies present in these
samples was determined by qRT-PCR.
Panel samples were shipped by regular post at ambient
temperature. We requested participant laboratories to resuspend
the samples in 100 ml of water and to analyze the material as
serum samples for nucleic acid detection of RVFV following their
routine protocols. The EQA panels were distributed to partici-
pants with documentation including full instructions and an
evaluation form to fill in their results. Participants were also asked
to report information on the adopted protocol, the type of RVFV
strain and the number of genome copies in each sample when
possible as well as any problems encountered concerning the
shipment or the packaging of the samples.
Evaluation of the results
To guarantee anonymous participation, an individual numerical
identification code was assigned to the results reported by each
laboratory. This number was followed by a letter (a, b, c) when
distinguishable data sets of results based on different methods were
sent.
The results were scored in reflection of analytical sensitivity and
specificity as in previous EQA studies performed by the ENIVD
[29,30]. We assigned one point for correct positive or negative
Author Summary
Rift Valley fever (RVF) is a zoonotic viral disease posing an
increasing threat to animals and humans worldwide.
Recent severe outbreaks of the disease in animal and
human populations in endemic regions and outside the
disease’s traditional geographic boundaries necessitate
the need for evaluating the diagnostic performance of RVF
expert laboratories. Molecular methods are increasingly
used for a rapid and accurate detection of viral nucleic
acid. In this study we present the results of the first
international external quality assessment (EQA) for the
molecular diagnosis of RVF. Such EQA studies allow
participating laboratories to monitor the quality and
identify possible weaknesses of current diagnostic meth-
ods. Participants to this RVF EQA were 30 expert
laboratories from 16 different countries worldwide. The
study demonstrated that optimal results could be
achieved by the majority of laboratories. Specific protocols
showed evenly good performances and can therefore be
recommended to all expert laboratories. However, other
methods showed uneven performances suggesting the
need for improved optimization and standardization of
these protocols.
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result whereas false-negative/-positive results were not scored.
Equivocal or borderline results were not counted as molecular
diagnostic methods should always provide a clear positive or
negative result.
Results were classified as:
N Optimal when all results were correct
N Acceptable when all correct results are reported except one
false-negative result
N Need for improvement when one or more false-positives and/
or several false-negative results were reported.
Results
We obtained from the invitees a response rate of 91%
representing a total of 30 participating laboratories from 16
different countries (10 European, 2 African, 3 Middle-Eastern/
Asian countries and one American country):
CODA-CERVA, Department of Virology, Epizootic Diseases
Section, Uccle, Belgium; ANSES, Virology Unit, Laboratory of
Lyon, France; CIRAD, Department BIOS «Control of exotic and
emerging diseases», Montpellier, France; IRBA-IMTSSA, Virol-
ogy Unit, Le Pharo, Marseille, France; BNI, National Reference
Centre for Tropical Infectious Diseases, Hamburg, Germany;
Bundeswehr Institute of Microbiology, Munich, Germany; Insti-
tute for Novel and Emerging Infectious Diseases Friedrich-
Loeffler-Institut, Germany; Robert Koch Institute, Berlin, Ger-
many; Institute of Virology, Georg-August University, Gottingen,
Germany; Central Virology Laboratory, Ministry of Health,
Public Health Laboratories Sheba Medical Center, Israel; Army
Medical and Veterinary Research Center, Rome, Italy; Depart-
ment of Infectious, Parasitic and Immune-Mediated Diseases,
Istituto Superiore di Sanità, Rome, Italy; Padiglione Baglivi
National Institute for Infectious Diseases ‘‘L. Spallanzani’’, Rome,
Italy; Department of Histology, Microbiology and Medical
Biotechnologies, University of Padova, Italy; Center for Vectors
and Infectious Diseases Research, National Institute of Health,
Aguas de Moura, Portugal; King Fahd Medical Research Center,
King Abdulaziz University, Saudi Arabia; Arboviruses and viral
hemorrhagic fever Unit, Institut Pasteur de Dakar, Senegal;
Defense Medical & Environmental Research Institute, DSO
National Laboratories, Singapore; Institute of Microbiology and
Immunology, Faculty of Medicine, University of Ljubljana,
Slovenia; Onderstepoort Veterinary Institute, South Africa;
Deltamune (Pty) Ltd, Centurion, Gauteng, South Africa; Special
Viral Pathogens Laboratory, National Institute for Communicable
Diseases, South Africa; Laboratory of Arboviruses and Imported
Viral Diseases, National Center for Microbiology, Instituto de
Salud Carlos III, Spain; National Institute for Agricultural
Research and Experimentation (INIA), Madrid, Spain; Viral
Diseases Unit, CReSA, Barcelona, Spain; Swedish Institute for
Infectious Disease Control, Sweden; Virology group, Spiez
Laboratory, Switzerland; Laboratory of Virology, University
Hospitals of Geneva, Switzerland; WHO Collaborative Centre
for Virus Reference and Research (Arboviruses & VHFs), Health
Protection Agency, United Kingdom; Viral Special Pathogens
Branch, Infectious Diseases, CDC, Atlanta, United States of
America.
A total of 39 datasets were received including 5 double sets from
laboratories using 2 methods (lab #6, 7, 21, 27 and 28) and 2
triple sets from lab #5 and #14. Methods used by the same
laboratory could differ from the type of technique, the protocol
used for a specific technique or the type of instrument used for a
specific protocol.
Performances varied among laboratories and scores ranged
from 7 to the maximum value of 14. Optimal results were reported
by 64% (n = 25) of the analyses; 21% (n = 8) of the analyses
achieved acceptable results due to the inability to detect one
positive sample, and 15% (n = 6) revealed several false negative
and/or one or more false positive results indicating that there is
still need for improvement (Table 2 and 3).
Several techniques were performed by the participating
laboratories for detection of RVFV RNA. Among the 39 datasets
received, we listed the use of real-time reverse transcription (qRT)-
PCR only (n = 32/82%), RT-nested PCR only (n = 3/8%), RT-
nested PCR and real-time RT-PCR combined (n = 2/5%), RT-
Loop-mediated isothermal amplification (RT-LAMP) (n = 1/
2,5%) and recombinase polymerase amplification (RPA) (n = 1/
2,5%) (Table 2 and 3).
Further information on the protocol applied for each diagnostic
test was requested from the participants. Concerning the 34 sets of
results obtained by qRT-PCR methods, 31 referred to published
protocols and 3 used in-house protocols. Among the diagnostic test
results referring to published protocols, 16 reported the use of the
protocol from Drosten et al., 2002 [24]; 8 referred to the protocol
of Bird et al. 2007 [25]; 4 applied the protocol from Weidmann et
al. published in 2008 [31]; one applied the protocol from Garcia et
al. in 2001 [23]; one applied the protocol from Busquets et al.
2010 [32] and one applied the protocol from Mweango et al. 2012
[33]. Regarding nested RT-PCR methods, 4 laboratories have
applied the protocol of Sall et al., published in 2002 [22] and one
laboratory applied the protocol from Sanchez-Seco et al., 2003
[34]. The sole set of results obtained by RT-LAMP adopted the
protocol published by Le Roux et al. in 2009 [26]. The only RPA
set of results was obtained by applying the protocol from Euler et
al. published in 2012 [27] with RPA reagents provided by
TwistDx. The diagnostic method employed for each set of results
Table 1. Proficiency panel sample composition.
Sample name Isolate Lineage Year Country Origin Accession n6
F057 Kenya 2007 SPU22/07/057 C 2007 Kenya human -
Tambul Egypt 1994 94EG Tambul A 1994 Egypt ovine HM587042
South Africa 1981, 20368 Ar20364 F 1981 South Africa mosquito HM587101
825/79 Zimbabwe 1979 VRL825/79 C 1979 Zimbabwe bovine HM587071
CAR R 1662, CA. Rep. 1985 CAR R1662 G 1985 Central African Republic human HM587086
AR 21229, Saudi Arabia 2000 Ar 21229 C 2000 Saudi Arabia mosquito -
Genetic lineages referred to as described by Grobbelaar et al [5].
doi:10.1371/journal.pntd.0002244.t001
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is specified in Table 2 and 3 as well as the references
corresponding to each protocol.
Performance comparisons between each type of technique are
limited as some methods are not sufficiently represented (e.g. n = 1
for RPA and RT-LAMP). For this reason a statistical analysis
could not reach any significant conclusion. Nevertheless some
general observations can be clearly delineated from the results.
The 32 datasets obtained by using qRT-PCR only, were all highly
scored with 13 or 14 points. Nevertheless it is interesting to notice
that the 2 datasets obtained with qRT-PCR combined with nested
RT-PCR scored 11 and 12 points demonstrating lower perfor-
mances than qRT-PCR alone. Laboratory #22 lost 2 points due
to 2 false positives generated by nested RT-PCR and thus would
have demonstrated optimal performances if considering the results
of the qRT-PCR only.
The maximum score of 14 was also obtained by the only set of
results reporting the use of RPA technology. On the other hand,
none of the methods involving nested RT-PCR achieved an
optimal performance and the corresponding scores ranged from 7
to 13. The dataset obtained with RT-LAMP showed a score of 11
mostly because of difficulties in detecting the less concentrated
samples.
The sensitivity of the different diagnostic methods can be
assessed by comparing the testing results of the serial dilutions of
RVFV-Kenya/2007 (samples #2, #9, #12, #4, and #14) and
RVFV-Egypt/1994 (samples #5 and #13). Observing the
percentage of correct results for each serial dilution, we observed
that all samples achieved a percentage over 90% except for the less
concentrated sample of RVFV-Egypt/1994 (sample #13) which
presented a percentage of correct results of 79% (Table 2 and 3).
Additionally, the most concentrated dilution of RVFV-Kenya/
2007 (sample #2) was the only sample of the serial dilution
samples to be detected by all techniques. This indicates a
correlation between increased dilution of the sample and low
sensitivity in RNA detection as expected.
Nevertheless, decreased sensitivity does not appear to be the
main reason for reporting false negatives. In fact, 38% of false
negatives (9 out of 24) may be attributed to decreased sensitivity as
these are corresponding to the false negatives obtained for the
sample with the lowest genome copy number (sample #13). The
rest of false negatives results were distributed equivalently among
the other samples, except for sample #2 (highly concentrated
dilution of RVFV-Kenya/2007) and sample #6 (RVFV-Zim-
babwe/1979) which presented 100% of correct results. Further-
more, it is interesting to note that several datasets (#9, 15, 21b and
29) revealed false negative results at lower dilutions of a serial
dilution but reported a positive correct result at a higher dilution
for the same strain. Such false negative results cannot be attributed
to sensitivity nor strain specificity issues but rather to the lack of
reproducibility and consistency of the employed test procedure.
This is a clear indication of the need to improve test procedures by
applying standardized protocols and accurate testing procedures.
When comparing test results obtained for the different RVFV
strains, we observed even performances indicating an overall good
specificity as the different techniques can detect several strain
types. However, some individual set of results indicated a potential
lack of specificity concerning methods such as the qRT-PCR
protocol from Garcia et al. [23] which was not able to detect both
dilutions of the RVFV-Egypt/1994 strain, and the nested RT-
PCR protocol of Sanchez-Seco et al. [34] which was not able to
detect the South-Africa/1981 strain and the Central-African-
Republic/1985 strain (Table 3). Nonetheless this information
should be interpreted with precaution as only one laboratory
reported the use of each of these protocols.
We can also have indications on the specificity of each
diagnostic method by analyzing the testing results of the two
negative controls (samples #7 and #8). Altogether, 8% of the
datasets (3 out of 39) reported false positives. Two of these 3
datasets originated from nested RT-PCR techniques, one reported
to use of the protocol of Sall et al. [22] and the other the protocol
of Sanchez-Seco et al. [34]. The third false positive was
engendered by qRT-PCR and indicated a low viral load (Table 3).
In order to evaluate practice in viral load determination,
participants were requested to provide the number of copies of
RVFV genome detected in positive samples. Over 73% of the
laboratories (22 out of 30) reported quantitative results and are
reported in bold in Table 3 and 3 although the numeric values are
not shown. The majority of these laboratories (14 out of 22) gave
their results as cycle threshold (Ct) values providing insufficient
data to estimate accurately viral load in the samples. Interestingly,
datasets providing no information on viral load originated not only
from techniques unable of providing quantitative results (RPA,
RT-LAMP and nested RT-PCR) but also from real time-based
procedures (6 out of 32) which are capable of determining
quantitative values (Table 2 and 3).
In order to assess capacity and experience in sequencing and
strain typing, participants were requested to specify the strain or
genotype of the RVFV detected in each positive sample. Only
13% (4 out of 30) of the laboratories reported specifications on the
strain type and only one data set reported this information for all
positive samples (data not shown).
Discussion
RVF reference laboratories responded keenly to this EQA study
(91% response rate), including laboratories situated in RVFV
endemic countries such as South Africa and Saudi Arabia.
Nonetheless, there is still a need to encourage more laboratories
situated in RVF-endemic areas to participate in quality assurance
programs. In fact, the increasing amplitude of this disease in Africa
necessitates the rapid recognition of RVF outbreaks and imple-
mentation of effective control measures in order to prevent
uncontrolled and wider spread of the virus.
Most of the laboratories (93%, 28 out of 30) reported the use of
qRT-PCR techniques allowing a rapid detection as well as
quantification of the virus genome. This confirms that the use of
qRT-PCR has remarkably expanded although it requires expen-
sive equipment. All datasets obtained by qRT-PCR only were
scored with 13 or 14 points indicating an evenly high performance
of all qRT-PCR procedures performed by the different laborato-
ries.
Protocols from Drosten et al, 2002 [24], Bird et al. 2007 [25],
Weidmann et al 2008 [31] as well as all in-house qRT-PCR
protocols (dataset #6b, #10 and #24) have demonstrated the
capacity of providing optimal performances indicating a good
specificity and sensitivity for these techniques. The sets of results
obtained by applying the qRT-PCR protocols of Mweango et al.
2012 [35], Garcia et al. 2001 [23] and Busquets et al. 2010 [32]
did not achieve optimal performances (scores 13, 11 and 13
respectively) but these techniques are not sufficiently represented
to conclude on their overall performances.
Information on the viral load of RVFV in human samples can
be very useful to monitor the progress of clinical manifestations
and to study the pathogenesis of RVFV. Interestingly, not all
laboratories employing qRT-PCR techniques have reported
quantified results and most of them (64%) reported the results as
cycle thereshold (Ct) values and not the number of genome copies.
This indicates that most laboratories do not resort to RVFV
Quality Assessment of Rift Valley Fever Diagnosis
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standards while performing qRT-PCR although such standards
would allow them to quantify viral genome in each sample without
performing any additional assay. Accordingly to the results of this
EQA as well as previous EQA studies, there is still room for
improvement concerning viral load determination [29,30].
The most widely used technique after qRT-PCR was nested
RT-PCR with 5 laboratories which referred to 2 different
protocols [22,34]. Nested RT-PCR performances varied greatly
compared to qRT-PCR with scores ranging from 7 to 13 thus
never reaching optimal performances. The dataset #14c obtained
a score of 13 with the protocol of Sall et al. 2002 [22] because it
could not detect the highest dilution of the RVFV-Egypt/1994
strain indicating a slightly low sensitivity just as observed for some
of the qRT-PCR methods. Nevertheless other datasets referring to
nested RT-PCR (#9 and #22) also reported false positive results
indicating a lack of specificity of these procedures with both nested
RT-PCR protocols [22,34].
It is interesting to notice the appearance of newly developed
techniques which are suitable for rapid field diagnostics such as
RT-LAMP developed in 2009 [26] and RPA technology
developed in 2012 [27]. No general conclusion can be achieved
concerning the performances of these two techniques as they both
have been performed by only one laboratory. However RPA has
shown optimal results for this EQA demonstrating equivalent
sensitivity and specificity to the qRT-PCR techniques (dataset
#27b).
On the other hand, RT-LAMP results indicated difficulties in
detecting RVFV genome in the less concentrated samples of the
panel (sample #4, #13 and #14). These results suggest some
limitations in test sensitivity. However, very high test sensitivity is
not essential for field diagnostics in an outbreak situation where
most diagnosed patients are in the acute phase of the disease and
are expected to present a high viremia.
Three laboratories have provided different sets of results which
referred to the same technique and protocol but using different
instruments (datasets #5b/c, #14a/b and #28 a/b). These
datasets provided all optimal results by using two different
instruments except for dataset #14 which reported a slightly
lower sensitivity using the SmartCycler System from Cepheid
(#14b, 13 points) compared to the 7500 Real-Time PCR System
from Applied Biosystems (#14a, 14 points). However, this
difference cannot be attributed with certainty to the use of a
different instrument as result variability can also arise from a lack
of repeatability of the procedure.
Only a few participants provided complete or partial informa-
tion regarding strain typing (13%, 4 out of 30). However, correct
results without strain or genetic lineage specification are satisfac-
tory in the context of laboratory diagnosis. Nonetheless, RVFV
strain typing is relevant for surveillance activities in order to
monitor which strains are circulating in RVFV-endemic areas and
what type of clinical manifestations are associated with these
strains.
Comparing the results of this EQA panel to previous EQA
studies [29,30,36], we observe a higher concordance in terms of
performance within laboratories using the same type of diagnostic
method. In fact, all qRT-PCR techniques demonstrated an
overall good performance with scores ranging from 13 to 14. On
the other hand, nested RT-PCR methods have shown a common
need for improvement in terms of test sensitivity and/or
specificity.
Nevertheless, variations in performance between laboratories
using the same method were noted. The reason for such variations
is difficult to establish but can be minimized by standardizing
procedures, including controls and testing conditions.
In order to ensure optimal performances for RVFV molecular
diagnosis in expert laboratories, we recommend conducting EQA
studies on a regular basis. Future EQA studies should include a
wide range of RVFV isolates with limiting concentrations to assess
as precisely as possible the diagnostic performances of various
molecular protocols in different reference laboratories.
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